Indication
Atypical hemolytic uremic syndrome
Atypical hemolytic uremic syndrome is a rare, life-threatening form of thrombotic microangiopathy characterized by uncontrolled activation of the alternative complement pathway. Read more about Atypical hemolytic uremic syndrome
4 drugs 3 manufacturers
Drugs that treat it
Common Atypical hemolytic uremic syndrome therapies.
ULTOMIRIS (ravulizumab-cwvz)
BKEMV (eculizumab-aeeb)
EPYSQLI (eculizumab-aagh)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonAtypical hemolytic uremic syndrome is a rare, life-threatening form of thrombotic microangiopathy characterized by uncontrolled activation of the alternative complement pathway.
This dysregulation causes widespread endothelial damage and systemic microvascular thrombosis, predominantly injuring the renal microvasculature while potentially involving the cardiovascular, central nervous, and gastrointestinal systems.
Clinically, it presents across pediatric and adult populations with the classic triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury.
Unlike typical hemolytic uremic syndrome, atypical hemolytic uremic syndrome is not caused by Shiga toxin-producing infections and frequently stems from genetic mutations or autoantibodies affecting complement regulatory proteins, carrying a significant risk of progression to end-stage renal disease.
- nih.gov
Atypical hemolytic uremic syndrome is a rare, life-threatening form of thrombotic microangiopathy characterized by uncontrolled activation of the alternative complement pathway This dysregulation causes widespread endothelial damage and systemic microvascular thrombosis, predominantly injuring the renal microvasculature while potentially involving the cardiovascular, central nervous, and gastrointestinal systems Clinically, it presents across pediatric and adult populations with the classic tria...
- nih.gov
Atypical hemolytic uremic syndrome is a rare, life-threatening form of thrombotic microangiopathy characterized by uncontrolled activation of the alternative complement pathway This dysregulation causes widespread endothelial damage and systemic microvascular thrombosis, predominantly injuring the renal microvasculature while potentially involving the cardiovascular, central nervous, and gastrointestinal systems Clinically, it presents across pediatric and adult populations with the classic tria...
- nih.gov
Atypical hemolytic uremic syndrome is a rare, life-threatening form of thrombotic microangiopathy characterized by uncontrolled activation of the alternative complement pathway
- kidneyfund.org
This dysregulation causes widespread endothelial damage and systemic microvascular thrombosis, predominantly injuring the renal microvasculature while potentially involving the cardiovascular, central nervous, and gastrointestinal systems
- nih.gov
Unlike typical hemolytic uremic syndrome, atypical hemolytic uremic syndrome is not caused by Shiga toxin-producing infections and frequently stems from genetic mutations or autoantibodies affecting complement regulatory proteins, carrying a significant risk of progression to end-stage renal disease
Personalize your experience
Follow Atypical hemolytic uremic syndrome and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.